241 related articles for article (PubMed ID: 24051437)
1. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.
Yoshimaru T; Komatsu M; Matsuo T; Chen YA; Murakami Y; Mizuguchi K; Mizohata E; Inoue T; Akiyama M; Yamaguchi R; Imoto S; Miyano S; Miyoshi Y; Sasa M; Nakamura Y; Katagiri T
Nat Commun; 2013; 4():2443. PubMed ID: 24051437
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
Yoshimaru T; Komatsu M; Miyoshi Y; Honda J; Sasa M; Katagiri T
Cancer Sci; 2015 May; 106(5):550-8. PubMed ID: 25736224
[TBL] [Abstract][Full Text] [Related]
3. Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.
Yoshimaru T; Aihara K; Komatsu M; Matsushita Y; Okazaki Y; Toyokuni S; Honda J; Sasa M; Miyoshi Y; Otaka A; Katagiri T
Sci Rep; 2017 May; 7(1):1821. PubMed ID: 28500289
[TBL] [Abstract][Full Text] [Related]
4. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
5. BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.
Kim NH; Yoshimaru T; Chen YA; Matsuo T; Komatsu M; Miyoshi Y; Tanaka E; Sasa M; Mizuguchi K; Katagiri T
PLoS One; 2015; 10(6):e0127707. PubMed ID: 26052702
[TBL] [Abstract][Full Text] [Related]
6. Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.
Yoshimaru T; Komatsu M; Tashiro E; Imoto M; Osada H; Miyoshi Y; Honda J; Sasa M; Katagiri T
Sci Rep; 2014 Dec; 4():7355. PubMed ID: 25483453
[TBL] [Abstract][Full Text] [Related]
7. Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.
Kim JW; Akiyama M; Park JH; Lin ML; Shimo A; Ueki T; Daigo Y; Tsunoda T; Nishidate T; Nakamura Y; Katagiri T
Cancer Sci; 2009 Aug; 100(8):1468-78. PubMed ID: 19496786
[TBL] [Abstract][Full Text] [Related]
8. A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells.
Yoshimaru T; Ono M; Bando Y; Chen YA; Mizuguchi K; Shima H; Komatsu M; Imoto I; Izumi K; Honda J; Miyoshi Y; Sasa M; Katagiri T
Nat Commun; 2017 May; 8():15427. PubMed ID: 28555617
[TBL] [Abstract][Full Text] [Related]
9. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
10. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
[TBL] [Abstract][Full Text] [Related]
11. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
12. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
13. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
[TBL] [Abstract][Full Text] [Related]
14. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
[TBL] [Abstract][Full Text] [Related]
15. The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation.
Toki S; Yoshimaru T; Matsushita Y; Aihara H; Ono M; Tsuneyama K; Sairyo K; Katagiri T
Cancer Sci; 2021 Oct; 112(10):4208-4219. PubMed ID: 34363714
[TBL] [Abstract][Full Text] [Related]
16. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
[TBL] [Abstract][Full Text] [Related]
17. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
[TBL] [Abstract][Full Text] [Related]
18. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
19. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
[TBL] [Abstract][Full Text] [Related]
20. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
Bentin Toaldo C; Alexi X; Beelen K; Kok M; Hauptmann M; Jansen M; Berns E; Neefjes J; Linn S; Michalides R; Zwart W
BMC Cancer; 2015 Aug; 15():588. PubMed ID: 26272591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
